Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105,841,018
-
Total 13F shares
-
6,195,241
-
Share change
-
+802,010
-
Total reported value
-
$6,444,304
-
Put/Call ratio
-
2.8%
-
Price per share
-
$1.04
-
Number of holders
-
29
-
Value change
-
+$751,052
-
Number of buys
-
14
-
Number of sells
-
12
Institutional Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q4 2024
As of 31 Dec 2024,
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,195,241 shares.
The largest 10 holders included
VANGUARD GROUP INC, Anson Funds Management LP, GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, BlackRock, Inc., Opus Capital Group, LLC, STATE STREET CORP, NORTHERN TRUST CORP, UBS Group AG, and XTX Topco Ltd.
This page lists
29
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.